Epizyme Inc (OQ:EPZM)

Jun 18, 2020 01:31 pm ET
 Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
These indications were approved under accelerated approval with a priority review, based on overall response rate and duration of response in the company’s Phase 2 clinical trial cohorts of FL patients with EZH2 mutations and wild-type EZH2. TAZVERIK received initial accelerated approval by FDA on January 23, 2020 for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
May 13, 2020 05:12 pm ET
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that multiple abstracts have been accepted for poster presentations during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, being held May 29-31, 2020.
May 04, 2020 06:30 am ET
Epizyme Reports Business Progress and First Quarter 2020 Financial Results
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results.
Apr 27, 2020 06:30 am ET
Epizyme Announces Date of First Quarter 2020 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.
Mar 20, 2020 06:30 am ET
Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the company has appointed Jeffery Kutok, M.D., Ph.D., as chief scientific officer. In this role, Dr. Kutok will direct the company’s scientific strategy, including preclinical research to support the devel
Feb 24, 2020 06:30 am ET
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2019 financial results.
Feb 18, 2020 06:30 am ET
Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences
Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences. Details of the events are below:
Feb 14, 2020 06:30 am ET
Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of Follicular Lymphoma
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for the accelerated approval of TAZVERIK™ (tazemetostat) for patients with relapsed or refractor
Jan 23, 2020 05:16 pm ET
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TAZVERIK™ (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not
Jan 06, 2020 06:30 am ET
Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it exercised its option to sell $50 million of its common stock to Royalty Pharma, pursuant to the terms of the
Dec 18, 2019 05:27 pm ET
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of patients with relapsed or refractory follicular lymphoma (FL), both with o
Dec 18, 2019 02:00 pm ET
Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 11 - 0 in favor of the benefit-risk profile of tazemetostat as a treatment for patients with metastatic or locally advanced epithe
Dec 18, 2019 07:05 am ET
Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, announced today that trading of its common stock has been halted. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting at 8:00 a.m. ET today to discuss Epizyme’s New Drug Application (NDA) for tazemetost
Dec 07, 2019 10:05 am ET
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral EZH2 inhibitor, as a monotherapy for patients with follicular lymphoma (FL), both with or wit
Dec 02, 2019 10:45 am ET
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the company’s New Drug Application (NDA) requesting accelerated approval for tazemetostat, an ora
Nov 05, 2019 07:00 am ET
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme
NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.  In addition, investment funds managed by Pharmakon Advisors agreed to provide $70 million in senior-secured loans with the possibility to fund up to $370 million over time....
Nov 04, 2019 07:00 am ET
Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2
Oct 30, 2019 06:30 am ET
Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced recent tazemetostat program updates, including successfully completing a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for its tazemetostat program for follicular lymphoma (FL), G9a program updates and third quarter 2019 financial
Sep 04, 2019 06:30 am ET
Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development executive, Victoria Richon, Ph.D., to the company’s board of directors. In conjunction with the new appointments, Beth Seidenberg, M.D., who has served o
Aug 29, 2019 06:30 am ET
Epizyme to Participate in Upcoming September Conferences
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences:
Aug 09, 2019 06:30 am ET
Epizyme Reports Business Progress and Second Quarter 2019 Results
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline highlights and reported second quarter 2019 financial results.
Aug 06, 2019 06:30 am ET
Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference
Epizyme, Inc. (Nasdaq:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Wedbush PacGrow 2019 Healthcare Conference on Tuesday, Aug. 13, 2019 at 10:55 a.m. ET in New York City.
Jul 25, 2019 06:30 am ET
Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
“We are thrilled with FDA’s acceptance of this first tazemetostat NDA submission for priority review, and to be an important step closer to achieving our mission of rewriting treatment for patients with cancer and other serious diseases,” said Robert Bazemore, president and chief executive officer of Epizyme. “This is a significant achievement in the development of this potentially first-in-class EZH2 inhibitor, and we look forward to working with FDA during the review. If approved, we believe tazemetostat could become an important new option in the treating physicians’ arsenal. We would like
Jul 22, 2019 06:30 am ET
Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019. Mr. Tombesi brings over 30 years of extensive financial and accounting expertise to Epizyme, most recently serving as the chief financial officer at Insmed, Incorpor
Jun 21, 2019 07:45 am ET
Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. The data show
Jun 12, 2019 06:30 am ET
Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with
Jun 03, 2019 06:30 am ET
Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported updated data on tazemetostat from the epithelioid sarcoma cohort of its ongoing Phase 2 study in patients with molecularly defined solid tumors. The data will be presented today in an
May 30, 2019 06:30 am ET
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithe
May 29, 2019 06:30 am ET
Epizyme to Present at Jefferies 2019 Healthcare Conference
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5, 2019 at 3:00 p.m. ET in New York City.
May 16, 2019 09:33 am ET
Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June.
May 06, 2019 06:30 am ET
Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2019 financial results.
Apr 03, 2019 08:20 am ET
Detailed Research: Economic Perspectives on CarMax, Cameco, American Renal Associates, Donaldson, Epizyme, and Tredegar — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of CarMax, Inc. (NYSE:KMX), Cameco Corporation (NYSE:CCJ), American Renal...
Mar 12, 2019 10:45 am ET
Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering
Mar 06, 2019 10:16 pm ET
Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock
Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deduc
Mar 06, 2019 04:01 pm ET
Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock
Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and prefe
Mar 05, 2019 06:30 am ET
Epizyme Announces Presentations at Upcoming March Investor Conferences
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences:
Feb 26, 2019 06:30 am ET
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2018 financial results.
Feb 19, 2019 06:30 am ET
Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018 financial results and present at the 8th Annual Leerink Partners Health Care
Jan 04, 2019 06:30 am ET
Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both w
Dec 18, 2018 06:30 am ET
Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of patient dosing in a Phase 1 clinical trial of GSK3368715, a first-in-class protein arginine methyl
Nov 15, 2018 06:35 am ET
Epizyme Announces Conference Call to Discuss Corporate Updates
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET.
Nov 09, 2018 08:00 am ET
Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Paramount Group, Inc. (NYSE:PGRE), Envestnet, Inc (NYSE:ENV), Assurant,...
Nov 02, 2018 06:30 am ET
Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the third quarter of 2018 and provided updates on its tazemetostat clinical development program. Tazemetostat is a first-in-class, selective, orally available EZH2 inhibitor, in development for hematologic
Oct 22, 2018 05:00 am ET
Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor. The data were presented by the study’s lead investigator, Mrinal Gounder, M.D., attending physician, Sarcoma Medical Oncology and Early Drug Development Services, Memorial Sloan Kettering Cancer Center, during the European Society for Medical Oncolo
Oct 17, 2018 07:45 am ET
Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook — Fundamental Analysis, Calculating Forward M
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC (NASDAQ:OXFD), Ascena Retail Group, Inc....
Oct 10, 2018 06:45 am ET
Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society
Oct 05, 2018 04:05 pm ET
Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriter of its
Oct 02, 2018 10:05 pm ET
Epizyme Announces Pricing of Public Offering of Common Stock
Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price of $9.00 per share, before underwriting discounts. In addition, Epizyme has granted the underwriter a 30-day option to purchase up to an additional 1,250,000 shares of common stock at the public offering price, less the underwriting discount. All of the shares in the offering are to be sold by Epizyme.
Oct 02, 2018 04:01 pm ET
Epizyme Announces Proposed Public Offering of Common Stock
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Epizyme.
Sep 24, 2018 06:30 am ET
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of its Phase 2 non-Hodgkin lymphoma trial.
Aug 29, 2018 07:00 am ET
Epizyme to Participate in Upcoming Investor Conferences
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences:
Aug 20, 2018 07:30 am ET
Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook — Fundamental Analysis, Calcu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blucora, Inc. (NASDAQ:BCOR), Sapiens International Corporation N.V....
Aug 02, 2018 07:00 am ET
Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the second quarter of 2018 and provided key business updates.
Jul 24, 2018 11:36 am ET
Epizyme Appoints Dr. Shefali Agarwal as Chief Medical Officer
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the appointment of Dr. Shefali Agarwal as chief medical officer, effective July 23, 2018. In this role, Dr. Agarwal will oversee all of the...
Jul 23, 2018 07:00 am ET
Epizyme Appoints Dr. Shefali Agarwal as Chief Medical Officer
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the appointment of Dr. Shefali Agarwal as chief medical officer, effective July 23, 2018. In this role, Dr. Agarwal will oversee all of the...
Jul 19, 2018 07:30 am ET
Epizyme Announces Date of Second Quarter 2018 Financial Results and Business Update Conference Call
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report its second quarter 2018 financial results on Thursday, August 2, 2018. Management will host a conference call and...
Jun 15, 2018 05:30 am ET
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced positive interim data from an ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor, as...
Jun 06, 2018 07:55 am ET
Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec — Future Expectations, Projections Moving
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Silicon Motion Technology Corporation (NASDAQ:SIMO), Green Brick Partners,...
Jun 03, 2018 09:00 am ET
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the first detailed results from the Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor,...
Jun 01, 2018 07:30 am ET
Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call at 8:30 a.m. ET on June 15, 2018 to discuss interim clinical data from adult patients with...
May 17, 2018 09:13 am ET
Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 trials of its lead candidate, tazemetostat, a potent, selective, orally available EZH2 inhibitor, will be...
May 08, 2018 07:30 am ET
Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the first quarter of 2018 and provided a business update. “We made meaningful progress with tazemetostat’s...
May 01, 2018 07:30 am ET
Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
First Quarter 2018 Financial Results to be Announced May 8, 2018
Apr 23, 2018 04:45 pm ET
Epizyme Provides Update Regarding Tazemetostat Clinical Program
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report...
Apr 11, 2018 07:55 am ET
Recent Analysis Shows Photronics, Just Energy Group, Baidu, Nomura Holdings Inc ADR, KT, and Epizyme Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Photronics, Inc. (NASDAQ:PLAB), Just Energy Group,...
Apr 09, 2018 06:45 pm ET
Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
Study Evaluated the Safety of Tazemetostat and Established the Recommended Phase 2 Dose; Anti-Tumor Activity Observed in Multiple Tumor Types
Mar 16, 2018 08:00 am ET
New Research: Key Drivers of Growth for GDS HOLDINGS, Nova Measuring Instruments, Magic Software Enterprises, Epizyme, United Community Financial, and Addus HomeCare — Factors of Influence, Major Init
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GDS HOLDINGS (NASDAQ:GDS), Nova Measuring Instruments...
Mar 13, 2018 07:30 am ET
Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019
Mar 12, 2018 04:30 pm ET
Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the appointment of Michael Giordano, M.D., to the company’s board of directors. Dr. Giordano brings to the...
Mar 12, 2018 06:30 am ET
Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the Oppenheimer & Co. 28th Annual Healthcare Conference at 10:20 a.m. ET...
Feb 27, 2018 06:30 am ET
Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and...
Feb 07, 2018 06:30 am ET
Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00...
Dec 11, 2017 07:31 am ET
Dec 10, 2017 10:00 am ET
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
Data Highlights Company's Innovative Work in Translational Medicine to Identify Non-Hodgkin Lymphoma Patient Populations That May Derive Most Benefit
Nov 09, 2017 06:30 am ET
Epizyme to Present at the Jefferies 2017 London Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present a company overview at the Jefferies 2017 London Healthcare Conference on Thursday, Nov....
Nov 01, 2017 04:02 pm ET
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates
Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17
Nov 01, 2017 04:02 pm ET
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates
Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17...
Sep 13, 2017 04:01 pm ET
Epizyme Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it intends to offer and sell $120 million of shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Epizyme....
Aug 15, 2017 06:30 am ET
Epizyme Announces Leadership Transition for Finance Organization
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership transition plan for its finance organization. Andrew E. Singer, executive vice president, finance and administration and chief financial officer of Epizyme, will be leaving the Company at the end of August to pursue other business opportunities. As part of this transition, Susan Graf, chief business officer of Epizyme, will assume responsibility for the finance organization going forward, including Epizym...
Jul 24, 2017 04:05 pm ET
Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the National Cancer Institute (NCI), part of the National Institutes of Health, has initiated its NCI-COG Pediatric MATCH study, which includes a phase 2 evaluation of tazemetostat as one of its treatment arms. Conducted under Epizyme’s Cooperative Research and Development Agreement (CRADA) executed with NCI in 2016, this multi-institutional study will evaluate tazemetostat as a monotherapy for pediatric patients...
Apr 20, 2017 10:05 am ET
Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will release its first quarter 2017 financial results on Monday, May 8, 2017....
Mar 09, 2017 06:32 am ET
Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter...
Mar 09, 2017 06:30 am ET
Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., will be retiring from Epizyme in the second quarter of 2017 to pursue advisory and other opportunities within the industry. Dr. Copeland has served in his role since 2008, and will remain a key advisor to Epizyme following his transition. The Company is executing plans for continued growth of its investigational pipeline, with plans...
Oct 31, 2016 06:30 am ET
Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered into two Cooperative Research and Development Agreements (CRADAs) with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). The CRADAs will evaluate tazemetostat, Epizyme’s first-in-class EZH2 inhibitor, and pinometostat, the Company’s first-in-class DOT1L inhibitor. Both investigational medicines target proteins implicated in the development and regulation of canc...
Oct 27, 2016 06:30 am ET
Epizyme to Report Business Highlights and Third Quarter 2016 Financial Results on November 3, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarter 2016 financial results....
Sep 29, 2016 06:30 am ET
Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance
CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the position of vice president of regulatory affairs and quality assurance. Strode will report to Epizyme’s president and chief executive officer, Robert Bazemore and will oversee all of the Company’s activities related to global regulatory strategy, including upcoming interactions with regulatory authorities regarding tazemetostat and global filings....
Sep 21, 2016 06:30 am ET
Epizyme Establishes Collaboration with Foundation Medicine to Support Tazemetostat Phase 2 Clinical Trial
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement with Foundation Medicine, Inc. to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma (NHL). Foundation Medicine’s SmartTrials™ Precision Enrollment Program and FoundationOne® Heme panel will assist in identifying a population of individuals with NHL who harbor ...
Sep 15, 2016 06:30 am ET
Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of patient dosing in a Phase 1 clinical trial of GSK3326595 (formerly EPZ015938), a first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor discovered by Epizyme and licensed to GSK. PRMT5 is a protein methyltransferase that is associated with a number of human cancers....
Aug 11, 2016 06:30 am ET
Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company’s global phase 2 study evaluating tazemetostat, a first-in-class EZH2 inhibitor, for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function....
Aug 08, 2016 06:30 am ET
Epizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018...
Aug 01, 2016 04:05 pm ET
Epizyme to Report Second Quarter 2016 Financial Results on August 8, 2016 and Participate in Upcoming Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the company’s multi-year vision, along with second quarter 2016 financial results....